To utilize pembrolizumab or cemiplimab as monotherapies in the initial treatment stage, it is necessary to have PD-L1 expression of more than 50%, which means that at least 50% of a minimum of 100 tumor cells (TCs) should show membrane expression of PD-L1. This evidence concerns the gene CD274 and neoplasm.